UK clinical trials company invests in Australian presence 28 May 2010 The UK-based research organisation Chiltern International Limited has launched operations in Victoria as part of the company’s expansion in the Asia-Pacific region. Established in London nearly thirty years ago, Chiltern International is highly experienced in conducting clinical trials from Early Phase to Late Phase across a broad therapeutic range, and in providing full clinical research services including Clinical Development and Biometrics. Chiltern has specialist therapeutic area teams in CNS (Central Nervous System), Infectious Diseases, Oncology, Ophthalmology, Paediatrics and Respiratory. The company employs some 1,400 people around the world, conducts clinical trials in over 40 countries, and plans to grow its workforce in the Asia- Pacific region to around 70 by the end of this year. Commenting on Chiltern’s expansion into the region, CEO Glenn Kerkhof, said “Asia-Pacific is one of the foremost emerging markets in our industry. “With the current expansion of pharmaceutical R&D needs into the Asia Pacific region, Chiltern is well positioned to meet the needs this growth entails.” More information |